Cardiomyopathies in China: A 2018–2019 state-of-the-art review

Cardiomyopathies are diseases of the cardiac muscle and are often characterized by ventricular dilation, hypertrophy, and cardiac arrhythmia. Patients with cardiomyopathies often experience sudden death and cardiac failure and require cardiac transplantation during the course of disease progression....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tian-Rui Hua, Shu-Yang Zhang
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2020
Materias:	Cardiomyopathies Genetics Heart failure Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/fd6b673fb7f84a53a24f7242b320fe6e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fd6b673fb7f84a53a24f7242b320fe6e
record_format	dspace
spelling	oai:doaj.org-article:fd6b673fb7f84a53a24f7242b320fe6e2021-12-02T13:57:40ZCardiomyopathies in China: A 2018–2019 state-of-the-art review2095-882X10.1016/j.cdtm.2020.05.006https://doaj.org/article/fd6b673fb7f84a53a24f7242b320fe6e2020-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X20300451https://doaj.org/toc/2095-882XCardiomyopathies are diseases of the cardiac muscle and are often characterized by ventricular dilation, hypertrophy, and cardiac arrhythmia. Patients with cardiomyopathies often experience sudden death and cardiac failure and require cardiac transplantation during the course of disease progression. Early diagnosis, differential diagnosis, and genetic consultation depend on imaging techniques, genetic testing, and new emerging diagnostic tools such as serum biomarkers. The molecular genetics of cardiomyopathies has been widely studied recently. The discovery of mechanisms underlying heterogeneity and overlapping of the phenotypes of cardiomyopathies has revealed the existence of disease modifiers, and this has led to the emergence of novel disease-modifying therapy. This 2018–2019 state-of-the-art review outlines the pathogenesis, diagnosis, and treatment of cardiomyopathies in China.Tian-Rui HuaShu-Yang ZhangKeAi Communications Co., Ltd.articleCardiomyopathiesGeneticsHeart failureMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 6, Iss 4, Pp 224-238 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cardiomyopathies Genetics Heart failure Medicine (General) R5-920
spellingShingle	Cardiomyopathies Genetics Heart failure Medicine (General) R5-920 Tian-Rui Hua Shu-Yang Zhang Cardiomyopathies in China: A 2018–2019 state-of-the-art review
description	Cardiomyopathies are diseases of the cardiac muscle and are often characterized by ventricular dilation, hypertrophy, and cardiac arrhythmia. Patients with cardiomyopathies often experience sudden death and cardiac failure and require cardiac transplantation during the course of disease progression. Early diagnosis, differential diagnosis, and genetic consultation depend on imaging techniques, genetic testing, and new emerging diagnostic tools such as serum biomarkers. The molecular genetics of cardiomyopathies has been widely studied recently. The discovery of mechanisms underlying heterogeneity and overlapping of the phenotypes of cardiomyopathies has revealed the existence of disease modifiers, and this has led to the emergence of novel disease-modifying therapy. This 2018–2019 state-of-the-art review outlines the pathogenesis, diagnosis, and treatment of cardiomyopathies in China.
format	article
author	Tian-Rui Hua Shu-Yang Zhang
author_facet	Tian-Rui Hua Shu-Yang Zhang
author_sort	Tian-Rui Hua
title	Cardiomyopathies in China: A 2018–2019 state-of-the-art review
title_short	Cardiomyopathies in China: A 2018–2019 state-of-the-art review
title_full	Cardiomyopathies in China: A 2018–2019 state-of-the-art review
title_fullStr	Cardiomyopathies in China: A 2018–2019 state-of-the-art review
title_full_unstemmed	Cardiomyopathies in China: A 2018–2019 state-of-the-art review
title_sort	cardiomyopathies in china: a 2018–2019 state-of-the-art review
publisher	KeAi Communications Co., Ltd.
publishDate	2020
url	https://doaj.org/article/fd6b673fb7f84a53a24f7242b320fe6e
work_keys_str_mv	AT tianruihua cardiomyopathiesinchinaa20182019stateoftheartreview AT shuyangzhang cardiomyopathiesinchinaa20182019stateoftheartreview
_version_	1718392297682370560

Cardiomyopathies in China: A 2018–2019 state-of-the-art review

Ejemplares similares